Scaling Palliative Care Requires Adherence to Best Practices
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
Source: ajmc.com
Adv Hematol News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Adv Hematol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Adv Hematol Today - Breaking & Trending Today
Investigators Set to Explore Selinexor Monotherapy or Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.
Source: onclive.com
Octapharma AG: Octapharma presents new data at ISTH 2023 in an ongoing commitment to improve the lives of people with bleeding disorders
LACHEN, Switzerland, June 6, 2023 /PRNewswire/ -- Octapharma to present new clinical and scientific findings for wilate®, Nuwiq®, octaplex® and atenativ® at the upcoming ISTH 2023 CongressNew
Source: finanznachrichten.de
Novartis UK: First STAMP (specifically targeting the abl myristoyl pocket) inhibitor for treatment for chronic myeloid leukaemia (CML), Scemblix? (asciminib) receives NICE final draft recommendation in Great Britain
Asciminib final draft recommended by the National Institute for Health and Care Excellence (NICE) for use for treatment of adult patients with Philadelphia chromosome-positive chronic myeloid
Source: finanznachrichten.de
Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A
Share this article Share this article LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ -- Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq ®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01...
Source: prnewswire.com